文献速递流行病学与生物统计医学教育与科研方法

肿瘤学临床试验透明度近年显著提升

The clinical trial transparency in oncology significantly increased over the recent years.
PubMed 文献 · J Clin Epidemiol · 2019-12-06

结果显示92%的试验已注册,其中76%为前瞻性注册,27%提供了试验方案,三项指标均呈显著上升趋势(均P < 0.001)。结论认为透明度虽有改善,但仍有提升空间。

要点

  • 肿瘤临床试验注册率92%,前瞻性注册率76%,方案公开率仅27%。
  • 注册、前瞻性注册和方案公开均呈显著逐年上升趋势(均P < 0.001)。
  • 样本量大于中位数的研究更可能注册和提供方案。

核心结论

  • 肿瘤临床试验的注册、前瞻性注册和方案公开率近年显著增加,但仍需改进。

主要发现

  • 625篇文章中92%已注册,其中76%为前瞻性注册,27%提供了试验方案。
  • 注册、前瞻性注册和方案公开均呈显著上升趋势(均P < 0.001)。
  • 入组数大于中位数的研究更可能注册(aOR 3.14,95%CI 1.21-8.15)和提供方案(aOR 3.84,95%CI 2.24-6.57)。
  • 非产业资助的研究更少前瞻性注册(aOR 0.37,95%CI 0.25-0.55),但更可能提供方案(aOR 1.69,95%CI 1.13-2.52)。

临床怎么用

  • 提示研究者和机构应继续推动前瞻性注册和方案公开,尤其针对非产业资助研究的前瞻性注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Persistent efforts have been made to promote clinical trial transparency, which included encouraging trial registration and prospective registration, as well as protocol disclosure. This study aims to analyze the extent of registration, prospective registration and protocol disclosure in oncology clinical trials and their changing trends. STUDY DESIGN AND SETTING: All phase II and phase III oncology clinical trials published in 5 major journals, the Annals of Oncology, the Journal of Clinical Oncology, JAMA Oncology, The Lancet Oncology, and The New England Journal of Medicine, between January 2013 and December 2017, were included. Data on trial characteristics as well as registration status and availability of protocol and its location were collected. RESULTS: In total, 625 articles were included, 92% were registered, of which 76% were prospectively registered. Overall, 27% provided protocols. Increasing trends were observed in registration, prospective registration, and protocol disclosure (all P < 0.001). Studies with enrollment number larger than median number were more likely to be registered (adjusted odds ratio (aOR), 3.14 [95% confidence interval (CI), 1.21-8.15]) and to provide protocols (aOR, 3.84 [95% CI, 2.24-6.57]) than those with smaller enrollment number. Studies with nonindustry funding was less likely to be prospectively registered (aOR, 0.37 [95% CI, 0.25-0.55]) but more likely to provide protocols (aOR, 1.69 [95% CI, 1.13-2.52]) than those with industry funding only. CONCLUSION: Although the rates of registration, prospective registration, and protocol disclosure of oncology trials have significantly increased over the years, there is still room for improvement.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Song SY, Kim E. The clinical trial transparency in oncology significantly increased over the recent years. J Clin Epidemiol. 2019. PMID: 31816417. doi:10.1016/j.jclinepi.2019.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。